Literature DB >> 19745166

Decreased expression and activity of cAMP phosphodiesterases in cardiac hypertrophy and its impact on beta-adrenergic cAMP signals.

Aniella Abi-Gerges1, Wito Richter, Florence Lefebvre, Philippe Mateo, Audrey Varin, Christophe Heymes, Jane-Lise Samuel, Claire Lugnier, Marco Conti, Rodolphe Fischmeister, Grégoire Vandecasteele.   

Abstract

RATIONALE: Multiple cyclic nucleotide phosphodiesterases (PDEs) degrade cAMP in cardiomyocytes but the role of PDEs in controlling cAMP signaling during pathological cardiac hypertrophy is poorly defined.
OBJECTIVE: Evaluate the beta-adrenergic regulation of cardiac contractility and characterize the changes in cardiomyocyte cAMP signals and cAMP-PDE expression and activity following cardiac hypertrophy. METHODS AND
RESULTS: Cardiac hypertrophy was induced in rats by thoracic aortic banding over a time period of 5 weeks and was confirmed by anatomic measurements and echocardiography. Ex vivo myocardial function was evaluated in Langendorff-perfused hearts. Engineered cyclic nucleotide-gated (CNG) channels were expressed in single cardiomyocytes to monitor subsarcolemmal cAMP using whole-cell patch-clamp recordings of the associated CNG current (I(CNG)). PDE variant activity and protein level were determined in purified cardiomyocytes. Aortic stenosis rats exhibited a 67% increase in heart weight compared to sham-operated animals. The inotropic response to maximal beta-adrenergic stimulation was reduced by approximately 54% in isolated hypertrophied hearts, along with a approximately 32% decrease in subsarcolemmal cAMP levels in hypertrophied myocytes. Total cAMP hydrolytic activity as well as PDE3 and PDE4 activities were reduced in hypertrophied myocytes, because of a reduction of PDE3A, PDE4A, and PDE4B, whereas PDE4D was unchanged. Regulation of beta-adrenergic cAMP signals by PDEs was blunted in hypertrophied myocytes, as demonstrated by the diminished effects of IBMX (100 micromol/L) and of both the PDE3 inhibitor cilostamide (1 micromol/L) and the PDE4 inhibitor Ro 201724 (10 micromol/L).
CONCLUSIONS: Beta-adrenergic desensitization is accompanied by a reduction in cAMP-PDE and an altered modulation of beta-adrenergic cAMP signals in cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19745166      PMCID: PMC2792993          DOI: 10.1161/CIRCRESAHA.109.197947

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  49 in total

Review 1.  Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family.

Authors:  Y Shakur; L S Holst; T R Landstrom; M Movsesian; E Degerman; V Manganiello
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

Review 2.  Cardiac excitation-contraction coupling.

Authors:  Donald M Bers
Journal:  Nature       Date:  2002-01-10       Impact factor: 49.962

3.  Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes.

Authors:  Jeremy Wechsler; Young-Hun Choi; Judith Krall; Faiyaz Ahmad; Vincent C Manganiello; Matthew A Movsesian
Journal:  J Biol Chem       Date:  2002-08-01       Impact factor: 5.157

4.  MYOCARDIAL NOREPINEPHRINE CONCENTRATION IN MAN. EFFECTS OF RESERPINE AND OF CONGESTIVE HEART FAILURE.

Authors:  C A CHIDSEY; E BRAUNWALD; A G MORROW; D T MASON
Journal:  N Engl J Med       Date:  1963-09-26       Impact factor: 91.245

5.  The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3.

Authors:  Cecile Terrenoire; Miles D Houslay; George S Baillie; Robert S Kass
Journal:  J Biol Chem       Date:  2009-02-13       Impact factor: 5.157

6.  Down regulation of myocardial beta1-adrenoceptor signal transduction system in pacing-induced failure in dogs with aortic stenosis-induced left ventricular hypertrophy.

Authors:  J Tse; M W Huang; R J Leone; H R Weiss; Y Q He; P M Scholz
Journal:  Mol Cell Biochem       Date:  2000-02       Impact factor: 3.396

7.  Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a.

Authors:  C L Antos; N Frey; S O Marx; S Reiken; M Gaburjakova; J A Richardson; A R Marks; E N Olson
Journal:  Circ Res       Date:  2001-11-23       Impact factor: 17.367

8.  Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure.

Authors:  Koki Takahashi; Tomohiro Osanai; Takao Nakano; Makoto Wakui; Ken Okumura
Journal:  Heart Vessels       Date:  2002-09       Impact factor: 2.037

9.  Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins.

Authors:  Stephen J Perry; George S Baillie; Trudy A Kohout; Ian McPhee; Maria M Magiera; Kok Long Ang; William E Miller; Alison J McLean; Marco Conti; Miles D Houslay; Robert J Lefkowitz
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

Review 10.  What is the role of beta-adrenergic signaling in heart failure?

Authors:  Martin J Lohse; Stefan Engelhardt; Thomas Eschenhagen
Journal:  Circ Res       Date:  2003-11-14       Impact factor: 17.367

View more
  46 in total

1.  Functional antagonism of β-adrenoceptor subtypes in the catecholamine-induced automatism in rat myocardium.

Authors:  D C Boer; J W M Bassani; R A Bassani
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

2.  Compartmentalized cyclic nucleotides have opposing effects on regulation of hypertrophic phospholipase Cε signaling in cardiac myocytes.

Authors:  Craig A Nash; Loren M Brown; Sundeep Malik; Xiaodong Cheng; Alan V Smrcka
Journal:  J Mol Cell Cardiol       Date:  2018-06-07       Impact factor: 5.000

Review 3.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

Review 4.  Compartmentalization of beta-adrenergic signals in cardiomyocytes.

Authors:  Yang K Xiang
Journal:  Circ Res       Date:  2011-07-08       Impact factor: 17.367

5.  Phosphodiesterase 4B in the cardiac L-type Ca²⁺ channel complex regulates Ca²⁺ current and protects against ventricular arrhythmias in mice.

Authors:  Jérôme Leroy; Wito Richter; Delphine Mika; Liliana R V Castro; Aniella Abi-Gerges; Moses Xie; Colleen Scheitrum; Florence Lefebvre; Julia Schittl; Philippe Mateo; Ruth Westenbroek; William A Catterall; Flavien Charpentier; Marco Conti; Rodolphe Fischmeister; Grégoire Vandecasteele
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

6.  PDE4B mediates local feedback regulation of β₁-adrenergic cAMP signaling in a sarcolemmal compartment of cardiac myocytes.

Authors:  Delphine Mika; Wito Richter; Ruth E Westenbroek; William A Catterall; Marco Conti
Journal:  J Cell Sci       Date:  2014-01-10       Impact factor: 5.285

7.  UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.

Authors:  Li Wang; Brian T Burmeister; Keven R Johnson; George S Baillie; Andrei V Karginov; Randal A Skidgel; John P O'Bryan; Graeme K Carnegie
Journal:  Cell Signal       Date:  2015-02-12       Impact factor: 4.315

8.  Interaction between phosphodiesterases in the regulation of the cardiac β-adrenergic pathway.

Authors:  Claire Y Zhao; Joseph L Greenstein; Raimond L Winslow
Journal:  J Mol Cell Cardiol       Date:  2015-09-23       Impact factor: 5.000

Review 9.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

10.  Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.

Authors:  Walid Mokni; Thérèse Keravis; Nelly Etienne-Selloum; Alison Walter; Modou O Kane; Valérie B Schini-Kerth; Claire Lugnier
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.